Suchergebnisse - "Usmani, Saad Z"

PubPharm (200)

1

Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in MajesTEC-1

enthalten in: Blood | 2024

von Cortes-Selva, D. | Perova, T. | Skerget, S. | +22

2

Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk

enthalten in: Blood cancer journal | 2024

von Callander, N. | Silbermann, R. | Kaufman, J. | +33

3

Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data

enthalten in: Advances in therapy | 2024

von Durie, B. | Kumar, S. | Ammann, E. | +5

4

Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone : Patient-reported outcomes from GRIFFIN

enthalten in: American journal of hematology | 2024

von Silbermann, R. | Laubach, J. | Kaufman, J. | +23

5

ASTCT Committee on Practice Guidelines Survey on Evaluation and Management of Relapsed/Refractory Multiple Myeloma after Failure of Chimeric Antigen Receptor T Cell Therapy

enthalten in: Transplantation and cellular therapy | 2024

von Hashmi, H. | Kumar, A. | Kharfan-Dabaja, M. | +10

6

Unscheduled healthcare interactions in multiple myeloma patients receiving T cell redirection therapies

enthalten in: Blood advances | 2024

von Howard, A. | Concepcion, I. | Wang, A. | +18

7

Patterns of CRS with Teclistamab in Relapsed/Refractory Multiple Myeloma patients with Prior T-Cell Redirection Therapy

enthalten in: Blood advances | 2024

von Hamadeh, I. | Shekarkhand, T. | Rueda, C. | +19

8

CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma

enthalten in: Blood advances | 2024

von Firestone, R. | McAvoy, D. | Shekarkhand, T. | +23

9

SOHO State of the Art Updates and Next Questions : Will CAR-T Replace ASCT in NDMM

enthalten in: Clinical lymphoma, myeloma & leukemia | 2024

von Jurgens, E. | Usmani, S.

10

Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study

enthalten in: British journal of haematology | 2024

von Nooka, A. | Kaufman, J. | Rodriguez, C. | +16

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[20]